{"result": "{\n    \"title\": \"Breast Cancer Research Community\",\n    \"summary\": \"The breast cancer research community revolves around a group of renowned authors and researchers who have made significant contributions to the field. The community is characterized by a network of relationships between these entities, with a focus on the study of breast cancer treatment and research.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for significant advancements in breast cancer research and treatment.\",\n    \"findings\": [\n        {\n            \"summary\": \"Key Researchers in the Community\",\n            \"explanation\": \"The breast cancer research community is led by a group of renowned authors and researchers, including Schneeweiss A, Schmid P, Iwata H, Adams S, Barrios CH, and Rugo HS. These individuals have made significant contributions to the field, with a focus on the study of breast cancer treatment and research [Data: Entities (692, 912, 780, 913, 915, 914)].\"\n        },\n        {\n            \"summary\": \"Research Focus on Breast Cancer Treatment\",\n            \"explanation\": \"The community's research focus is on the study of breast cancer treatment, with a particular emphasis on the treatment of advanced triple-negative breast cancer. This is evident in the numerous studies conducted by community members on the combination of atezolizumab and nab-paclitaxel in this type of cancer [Data: Relationships (590, 591, 616, 676, 678, 677)].\"\n        },\n        {\n            \"summary\": \"Collaboration and Co-Authorship\",\n            \"explanation\": \"The community is characterized by a high level of collaboration and co-authorship between its members. This is evident in the numerous studies that have been co-authored by multiple community members [Data: Relationships (590, 591, 616, 676, 678, 677)].\"\n        },\n        {\n            \"summary\": \"Significant Contributions to the Field\",\n            \"explanation\": \"The community's members have made significant contributions to the field of breast cancer research, with a focus on the study of breast cancer treatment and research. This is evident in the numerous studies and publications produced by community members [Data: Entities (692, 912, 780, 913, 915, 914)].\"\n        },\n        {\n            \"summary\": \"Potential for Significant Advancements\",\n            \"explanation\": \"The community's research has the potential to lead to significant advancements in the treatment and understanding of breast cancer. This is evident in the community's focus on the study of breast cancer treatment and research, as well as the numerous studies and publications produced by community members [Data: Entities (692, 912, 780, 913, 915, 914)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n692,\"\"\"SCHNEEWEISS A\"\"\",\"Here is a comprehensive summary of the data:\n\nSchneeweiss A is a researcher who has been involved in multiple studies on breast cancer. Specifically, they have conducted research on neoadjuvant carboplatin in early breast cancer, as well as the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Additionally, Schneeweiss A has authored research papers on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, and has authored multiple studies on breast cancer in general.\",8\r\n912,\"\"\"SCHMID P\"\"\",\"Here is a comprehensive summary of the data:\n\nSchmid P is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Schmid P is the author of a study on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, demonstrating expertise in this area. Furthermore, Schmid P has authored multiple studies on breast cancer, showcasing a broader range of research interests and expertise in the field.\",5\r\n693,\"\"\"CHIA S\"\"\",\"\"\"Chia S is a researcher involved in the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",1\r\n696,\"\"\"ENIU A\"\"\",\"\"\"Eniu A is a researcher involved in the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",1\r\n695,\"\"\"HARVEY V\"\"\",\"\"\"Harvey V is a researcher involved in the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",1\r\n676,\"\"\"HEGG R\"\"\",\"Here is a comprehensive summary of the data:\n\nHegg R is a researcher who has been involved in multiple studies related to breast cancer treatment. Specifically, they have contributed to research on the combination of pertuzumab, trastuzumab, and docetaxel for the treatment of metastatic breast cancer. Additionally, they have studied the combination of pertuzumab and trastuzumab with standard neoadjuvant chemotherapy regimens in patients with HER2-positive early breast cancer.\",1\r\n694,\"\"\"HICKISH T\"\"\",\"\"\"Hickish T is a researcher involved in the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",1\r\n697,\"\"\"WALDRON-LYNCH M\"\"\",\"\"\"Waldron-Lynch M is a researcher involved in the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",1\r\n780,\"\"\"IWATA H\"\"\",\"Here is a comprehensive summary of the data:\n\nIwata H is a renowned author in the medical field, with a significant body of work focused on breast cancer research. Specifically, Iwata H is an author of multiple studies on breast cancer, showcasing their expertise and dedication to the field. One of their notable studies is on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, highlighting their contribution to the understanding and treatment of this specific type of breast cancer. Overall, Iwata H's work has made a significant impact in the medical community, particularly in the area of breast cancer research and treatment.\",2\r\n913,\"\"\"ADAMS S\"\"\",\"Here is a comprehensive summary of the data:\n\nAdams S is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Adams S is the author of a study on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, demonstrating expertise in this area. Furthermore, Adams S has authored multiple studies on breast cancer, showcasing a broader range of research interests and expertise in the field.\",1\r\n915,\"\"\"BARRIOS CH\"\"\",\"Here is a comprehensive summary of the data:\n\nBarrios CH is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, they have conducted studies on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, as well as multiple studies on breast cancer in general.\",1\r\n914,\"\"\"RUGO HS\"\"\",\"Here is a comprehensive summary of the data:\n\nRugo HS is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Rugo HS is the author of a study on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, demonstrating expertise in this area. Furthermore, Rugo HS has authored multiple studies on breast cancer, showcasing a broad range of research interests and expertise in the field.\",1\r\n779,\"\"\"MOY B\"\"\",\"\"\"Moy B is an author of a medical study.\"\"\",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n590,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"VON MINCKWITZ G\"\"\",\"Here is a comprehensive summary of the data:\n\nSCHNEEWEISS A and VON MINCKWITZ G are co-authors of a research paper and a study on neoadjuvant carboplatin in early breast cancer.\n\nNote: I have concatenated the descriptions to provide a single, comprehensive summary, and resolved any potential contradictions to ensure a coherent output.\",17\r\n591,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"SCHMID P\"\"\",\"Here is a comprehensive summary of the data:\n\nSchmid P and Schneeweiss A are co-authors of multiple studies on breast cancer, specifically including a study on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions, ensuring that the summary includes all the relevant information and is written in third person.\",13\r\n585,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"CHIA S\"\"\",\"\"\"Schneeweiss A and Chia S are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n588,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"ENIU A\"\"\",\"\"\"Schneeweiss A and Eniu A are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n587,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"HARVEY V\"\"\",\"\"\"Schneeweiss A and Harvey V are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n582,\"\"\"HEGG R\"\"\",\"\"\"SCHNEEWEISS A\"\"\",\"\"\"Schneeweiss A and Hegg R are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n586,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"HICKISH T\"\"\",\"\"\"Schneeweiss A and Hickish T are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n589,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"WALDRON-LYNCH M\"\"\",\"\"\"Schneeweiss A and Waldron-Lynch M are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n616,\"\"\"IWATA H\"\"\",\"\"\"SCHMID P\"\"\",\"Here is a comprehensive summary of the data:\n\nSchmid P and Iwata H are co-authors of multiple studies on breast cancer, specifically focusing on the treatment of advanced triple-negative breast cancer. One of these studies examines the combination of atezolizumab and nab-paclitaxel in the treatment of this type of cancer.\n\nNote: I resolved the contradiction by combining the information from both descriptions, highlighting the specific focus on advanced triple-negative breast cancer and the broader scope of their research on breast cancer.\",7\r\n676,\"\"\"SCHMID P\"\"\",\"\"\"ADAMS S\"\"\",\"Here is a comprehensive summary of the data:\n\nSchmid P and Adams S are co-authors of multiple studies on breast cancer, specifically including a study on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions, ensuring that the summary includes all the relevant information and is written in a coherent and concise manner.\",6\r\n678,\"\"\"SCHMID P\"\"\",\"\"\"BARRIOS CH\"\"\",\"Here is a comprehensive summary of the data:\n\nSchmid P and Barrios CH are co-authors of multiple studies on breast cancer, specifically including a study on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.\n\nNote: I resolved the potential contradiction by combining the two descriptions, as they are not mutually exclusive. The first description provides specific information about one study, while the second description provides a broader context about the authors' work on breast cancer.\",6\r\n677,\"\"\"SCHMID P\"\"\",\"\"\"RUGO HS\"\"\",\"Here is a comprehensive summary of the data:\n\nSchmid P and Rugo HS are co-authors of multiple studies on breast cancer, specifically including a study on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions, ensuring that the summary includes all the relevant information and is written in third person.\",6\r\n615,\"\"\"MOY B\"\"\",\"\"\"IWATA H\"\"\",\"\"\"Moy B and Iwata H are co-authors of a medical study.\"\"\",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}